Cantargia
3.79 SEK -0.26%1,317 investors are following this company
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CANTA
Daily low / high price
3.724 / 3.972
SEK
Market cap
696.17M SEK
Turnover
583.69K SEK
Volume
154K
Latest videos
Financial calendar
Interim report
28.08.2024
Interim report
15.11.2024
Annual report
21.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fjärde AP-fonden | 9.9 % | 9.9 % |
Första AP-Fonden | 7.1 % | 7.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Cantargia presents Phase 2 clinical data in pancreatic cancer with nadunolimab at ESMO Gastrointestinal Cancer Congress 2024
Cantargia reports further progress in ongoing phase 1 clinical trial with CAN10
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Cantargia strengthen management team with the appointment of Ton Berkien as Chief Business Officer
Cantargia ASCO presentation highlights positive clinical data on nadunolimab counteracting neuropathy
Cantargia presents new positive clinical data on nadunolimab counteracting chemotherapy induced neuropathy
Annual General Meeting in Cantargia AB (publ)
Redeye: Cantargia Q1 2024 - Notable Cost Reductions
![Cantargia, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/512cf559-65c1-4b30-929f-bb2747ae4066.png)